CB-010 + cyclophosphamide + fludarabine

CB-010 + cyclophosphamide + fludarabine is a combination regimen used in clinical trials for the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma. CB-010 is a CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy derived from healthy donor T cells using hybrid RNA-DNA genome editing. Three genome edits are introduced: knockout of the T cell receptor alpha constant (TRAC) gene to eliminate TCR expression (reducing GVHD risk), insertion of a CD19-specific chimeric antigen receptor (CAR) into the TRAC locus, and knockout of the PD-1 gene to delay CAR-T exhaustion and enhance antitumor activity. Cyclophosphamide and fludarabine are small-molecule chemotherapeutics used sequentially for lymphodepletion prior to infusion of CB-010, increasing CAR-T cell engraftment and efficacy. The combination is administered intravenously in a sequential regimen and is being developed in clinical trials primarily for relapsed/refractory B-cell non-Hodgkin lymphoma, including large B-cell lymphoma, mantle cell lymphoma, follicular lymphoma, and marginal zone lymphoma[1][3][5][7].